Press review
The essentials of recent medical publications, unpacked by our newsroom into a clear, sourced digest, specialty by specialty.
OncologyTriple-negative: a new targeted weapon?
By Ana Espino | Published on October 28, 2025 | 3 min readTriple-negative breast cancer (TNBC) accounts for about 15% of all breast cancers. Its prognosis is poor, particularly in the metastatic stage. Its biology—characterized by the absence of hormone receptors (ER, PR) and HER2—limits the effectiveness of conventional targeted therapies. In addition, recurrence is common, and patients have few
OncologyRehabilitation, an often underestimated lever
By Ana Espino | Published on October 27, 2025 | 3 min readAlthough breast cancer is being treated more and more effectively, it often leaves significant physical aftereffects following surgery: chronic pain, upper-limb lymphedema, loss of mobility, and persistent fatigue. These symptoms directly affect quality of life and the return to independence. Yet, functional rehabilitation remains inconsist
OncologyWhat if physical exercise were the key to clearing “chemo brain” after breast cancer?
By Lila Rouland | Published on October 27, 2025 | 3 min readBreast cancer, affecting more than 2.3 million women each year, often leads to lasting aftereffects well beyond treatment. Among them, cancer-related cognitive impairment (CRCI) affects up to 70% of patients, with symptoms such as memory loss, difficulty concentrating, and mental slowing—often described as “chemo brain.” Even when mild, t
OncologyctDNA: promise of precision or reflection of inequality?
By Ana Espino | Published on October 24, 2025 | 3 min readBreast cancer is the most common malignancy among women worldwide. Despite major therapeutic advances, a substantial proportion of patients remain at risk of relapse, particularly those with residual disease after neoadjuvant therapy. Residual disease is a strong prognostic factor for early recurrence, especially in aggressive subtypes such
OncologyBrain under pressure: the ultimate frontier?
By Ana Espino | Published on October 23, 2025 | 3 min readBrain metastases are a frequent and severe complication of advanced cancers, particularly non–small cell lung cancer (NSCLC) and metastatic breast cancer (MBC). They significantly worsen prognosis and quality of life, while remaining difficult to manage due to the blood–brain barrier (BBB), which limits the penetration of conventional chemo
PsychiatryVirtual cognitive behavioral therapy: a digital shift in mental health care
By Carolina Lima | Published on October 23rd, 2025 | 3 min readIn recent years, mental health care has undergone a significant transformation, with digital tools reshaping how therapy is delivered. Among these innovations, virtual cognitive behavioral therapy (eCBT) has emerged as a promising alternative to traditional in-person therapy, offering flexibility, accessibility, and comparable clinical
OncologyTNBC after chemotherapy: can immunotherapy change the game?
By Ana Espino | Published on October 22, 2025 | 3 min readTriple-negative breast cancer (TNBC), characterized by the absence of hormonal receptors and HER2 expression, accounts for approximately 15–20% of all breast cancer cases. It is associated with a high risk of recurrence and early metastasis. Among patients who present with residual invasive disease after neoadjuvant chemotherapy, the progno
OncologyTNBC: exploring the global landscape of biomarkers and therapeutic prospects
By Lila Rouland | Published on October 22, 2025 | 3 min readTriple-negative breast cancer (TNBC) is characterized by the absence of hormonal receptors (ER, PR) and the HER2 protein. This particularity significantly limits targeted therapeutic options, leading to a poor prognosis marked by high recurrence and low overall survival rates. Given the biological heterogeneity of TNBC, global research ef
OncologyTriple-negative breast cancer: can spatial and single-cell profiling predict response to immunotherapy and radiation?
By Lila Rouland | Published on October 21, 2025 | 3 min readTriple-negative breast cancer (TNBC), lacking hormonal and HER2 receptors, represents an aggressive and heterogeneous subtype. Immune checkpoint inhibitors (ICIs), such as pembrolizumab, have recently shown therapeutic potential; however, only about 20% of metastatic patients respond to monotherapy. This highlights the urgent need for pre
OncologyTNBC: could everything be happening in the mitochondria?
By Ana Espino | Published on October 21, 2025 | 4 min readTriple-negative breast cancer (TNBC) is a particularly aggressive form of cancer, characterized by the absence of hormone receptors (ER/PR) and HER2. It primarily affects younger women, progresses rapidly, and carries a high risk of relapse, especially due to the lack of exploitable therapeutic targets. Currently, chemotherapy remains the s
OncologyTriple blow, triple clinical challenge
By Ana Espino | Published on October 20, 2025 | 3 min readThe synchronous development of several primary cancers is a rare but increasingly observed phenomenon, particularly in patients carrying genetic mutations such as BRCA1. In this particular case, the coexistence of triple-negative breast cancer and rectal adenocarcinoma is all the more complex as it may occur in patients with chronic hepatit
OncologyCapivasertib + Fulvestrant: the right choice after CDK4/6 inhibitor failure?
By Ana Espino | Published on October 17, 2025 | 3 min readMetastatic HR+/HER2– breast cancer — the most common subtype in postmenopausal women — remains an incurable disease despite advances in endocrine therapy and CDK4/6 inhibitors. Most patients eventually develop secondary resistance, limiting therapeutic options. Alterations in the PI3K/AKT/PTEN pathway, frequently observed in this subtype, c